Real-world Efficacy and Safety of Peptide Receptor Radionuclide Therapy in Japanese Neuroendocrine Tumor Patients
Comment on "Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study".
Abstract
A multicenter retrospective study analyzed 422 Japanese patients with unresectable neuroendocrine neoplasms receiving peptide receptor radionuclide therapy (PRRT).